NBI-921352

DRUG4 trials

Sponsors

Neurocrine Biosciences

Conditions

Focal Onset EpilepsyFocal Onset SeizureSCN8A Developmental and Epileptic Encephalopathy Syndrome

Phase 2

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

TerminatedNCT04873869

Neurocrine BiosciencesSCN8A Developmental and Epileptic Encephalopathy Syndrome

Start: 2022-01-31End: 2023-03-17Updated: 2025-10-16

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

CompletedNCT05159908

Neurocrine BiosciencesFocal Onset Epilepsy, Focal Onset Seizure

Start: 2021-11-08End: 2023-08-21Updated: 2024-09-26

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

TerminatedNCT05226780

Neurocrine BiosciencesSCN8A Developmental and Epileptic Encephalopathy Syndrome

Start: 2022-07-12End: 2025-11-12Updated: 2026-05-27

Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

TerminatedNCT05493293

Neurocrine BiosciencesFocal Onset Epilepsy, Focal Onset Seizure

Start: 2022-11-09End: 2024-03-11Updated: 2024-04-12